Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 28, 2025 07:00 ET | Source: Biomed Valley Discoveries, Inc.

Biomed Valley Discoveries Announces First Patient Dosed in Phase 1/2 Combination Study of Ulixertinib with Ruxolitinib (Jakafi®) in Patients with Myelofibrosis

Biomed Valley Discoveries announces first patient dosed in Phase 1/2 Combination Study of ulixertinib with ruxolitinib in patients with myelofibrosis.
August 13, 2024 08:00 ET | Source: Biomed Valley Discoveries, Inc.

Biomed Valley Discoveries Announces First Patient Dosed in Phase 2 Study of Its First-in-Class ERK 1/2 Inhibitor Ulixertinib in People with Histiocytosis

Biomed Valley Discoveries today announced that the first patient has been dosed in a Phase 2 study of ulixertinib for the treatment of histiocytosis.